World CDx 2026 has ended. This guide stays up as the record of who was there. Next: World CDx 2027, Aug 30 – Sep 2, 2027 in Boston
AI-enabled precision medicine at World CDx 2026
Oct 5–8, 2026 Boston, MA ~900 attendees Website
36 organizations at World CDx 2026 present work in multimodal & ai-enabled precision medicine: 23 technology and service providers, 9 drug developers and 4 academic, government and non-profit bodies. Between them they bring 52 presentations to the program. Most represented: Bristol Myers Squibb (3 on the program), GSK (3 on the program), AstraZeneca (2 on the program). As of Oct 8, 2026.
Format
Top represented
Showing 1–13 of 36 organizations
| Organization | World CDx 2026 Attendance |
|---|---|
Bristol Myers Squibb Princeton, NJ | |
Global pharmaceutical company with medicines in oncology, hematology, immunology and cardiovascular disease. | Panel Tue Oct 6 6:10pm Strengthening Tumor‑Informed MRD Assays with Standardized Analytical Validation to Ensure Reliable Detection & Confident Clinical Interpretation Liquid biopsy & MRDClinical & companion diagnostic development Panel Wed Oct 7 2:10pm Beyond IHC Scoring: Unlocking Next-Generation Clinical Biomarkers through AI-Powered Computational Pathology Digital pathology & spatial biomarkersMultimodal & AI-enabled precision medicine Panel Wed Oct 7 3:10pm Bolstering Scalable Commercial Drug-Diagnostic Strategies to Ensure Equitable Solutions for Global Precision Oncology Applications Drug–diagnostic commercialization & access Panel Thu Oct 8 9:00am Mobilizing Precision Cancer Care Through the Precision Cancer Consortium to Standardize Testing Pathways & Reduce Access Barriers Drug–diagnostic commercialization & access |
GSK London, UK | |
Global biopharmaceutical company developing vaccines and specialty medicines in infectious disease, HIV, respiratory, immunology and oncology. | Panel Tue Oct 6 6:10pm Strengthening Tumor‑Informed MRD Assays with Standardized Analytical Validation to Ensure Reliable Detection & Confident Clinical Interpretation Liquid biopsy & MRDClinical & companion diagnostic development Panel Wed Oct 7 9:00am Applying AI & Advanced Data Analytics to Transform Biomarker Discovery & Clinical Trial Strategy for Improved Precision Medicine Programs Multimodal & AI-enabled precision medicineBiomarker discovery & translation Panel Wed Oct 7 12:10pm Building the Clinical & Commercial Ecosystem for AI-Enabled Precision Pathology Digital pathology & spatial biomarkersDrug–diagnostic commercialization & access Talk Thu Oct 8 9:50am When a Drug Program Expects Multiple Global Dx Partners: Considerations for Master CDx Agreements Clinical & companion diagnostic developmentDrug–diagnostic commercialization & access |
AstraZeneca Cambridge, UK | |
Global pharmaceutical company with a large oncology portfolio, including targeted therapies and antibody-drug conjugates that rely on biomarker testing. | Talk Tue Oct 6 8:15am Enabling Access to Novel Computational Biomarkers: From Innovation to Impact Multimodal & AI-enabled precision medicineDrug–diagnostic commercialization & access Talk Wed Oct 7 11:50am Combining Foundation & Mathematical Models for Biomarker Discovery Multimodal & AI-enabled precision medicineBiomarker discovery & translation Panel Wed Oct 7 3:10pm Realizing the Promise, Gaps & Platform Innovation for Precision Medicine at Scale from Global Technology Leaders Multimodal & AI-enabled precision medicine Panel Thu Oct 8 9:00am Mobilizing Precision Cancer Care Through the Precision Cancer Consortium to Standardize Testing Pathways & Reduce Access Barriers Drug–diagnostic commercialization & access |
Microsoft Redmond, WA | |
Technology company whose cloud, data and AI services are used by healthcare and life science organizations. | Talk Wed Oct 7 11:50am Advancing Pharma Agentic R&D at Scale Multimodal & AI-enabled precision medicine Panel Wed Oct 7 12:50pm Embed, Don’t Disrupt: AI Diagnostics That Scale Multimodal & AI-enabled precision medicineDrug–diagnostic commercialization & access Panel Wed Oct 7 3:10pm Realizing the Promise, Gaps & Platform Innovation for Precision Medicine at Scale from Global Technology Leaders Multimodal & AI-enabled precision medicine |
Caris Life Sciences Irving, TX | ◇Expertise Partner |
Molecular profiling company using whole-exome and whole-transcriptome sequencing plus AI on a large clinico-genomic database for therapy selection and drug development. | Panel Tue Oct 6 5:10pm The Role of AI in the Future of Companion Diagnostics Multimodal & AI-enabled precision medicineClinical & companion diagnostic development Panel Wed Oct 7 11:20am Beyond the Slide: Tissue AI as the Anchor for Multimodal Biomarker Discovery & Global Deployment Digital pathology & spatial biomarkersMultimodal & AI-enabled precision medicine |
Natera Austin, TX | ◇Expertise Partner |
Cell-free DNA testing company whose Signatera test tracks molecular residual disease, with a real-world data platform for drug developers. | Talk Tue Oct 6 8:35am What Becomes Possible Combing MRD, Multi-Omics & RWD Insights Liquid biopsy & MRDMultimodal & AI-enabled precision medicine Talk Thu Oct 8 11:00am Accelerate Early Phase Drug Development with MIIRA, Natera’s Longitudinal ctDNA & Multi-Modal Real-World Data Platform Liquid biopsy & MRDMultimodal & AI-enabled precision medicine |
Pfizer New York, NY | |
Global pharmaceutical company with medicines and vaccines across many areas, including oncology drugs such as antibody-drug conjugates. | Panel Wed Oct 7 2:10pm Beyond IHC Scoring: Unlocking Next-Generation Clinical Biomarkers through AI-Powered Computational Pathology Digital pathology & spatial biomarkersMultimodal & AI-enabled precision medicine Panel Wed Oct 7 3:10pm Innovating Global Rx-Dx Trial Pathways Through Strategic & Compliant Co-Development Partnerships to Deliver Harmonized Precision Medicine Solutions Clinical & companion diagnostic developmentDrug–diagnostic commercialization & access |
CellCarta Montreal, Canada | ◇Program Partner |
Specialty laboratory CRO offering immunology, histopathology, proteomics and genomics testing and sample management for biomarker work in global clinical trials. | Chair Tue Oct 6 2:00pm Chair’s Opening Afternoon Remarks Panel Wed Oct 7 11:20am Beyond the Slide: Tissue AI as the Anchor for Multimodal Biomarker Discovery & Global Deployment Digital pathology & spatial biomarkersMultimodal & AI-enabled precision medicine Talk Wed Oct 7 12:10pm The CDx Model Needs to Change – What China Taught Us About Breaking Silos, Moving Faster, & Going Global Clinical & companion diagnostic developmentDrug–diagnostic commercialization & access Talk Thu Oct 8 11:00am Can AI Predict ADC Response? Multimodal & AI-enabled precision medicineBiomarker discovery & translation |
Gilead Sciences Foster City, CA | |
Biopharmaceutical company with marketed medicines in HIV, liver disease, oncology and inflammation, including antibody-drug conjugates and CAR T therapies. | Panel Wed Oct 7 11:20am Beyond the Slide: Tissue AI as the Anchor for Multimodal Biomarker Discovery & Global Deployment Digital pathology & spatial biomarkersMultimodal & AI-enabled precision medicine Panel Wed Oct 7 2:10pm Beyond IHC Scoring: Unlocking Next-Generation Clinical Biomarkers through AI-Powered Computational Pathology Digital pathology & spatial biomarkersMultimodal & AI-enabled precision medicine Talk Wed Oct 7 2:40pm Promise & Pitfalls of Tumor Target Quantification in Antibody-Drug Conjugate & Immune Cell Engager Drug Development Biomarker discovery & translationDigital pathology & spatial biomarkers |
Sanofi Paris, France | |
French pharmaceutical company developing medicines and vaccines in immunology, rare diseases, neurology and oncology. | Talk Wed Oct 7 8:10am Accelerating Target Discovery & Precision Medicine Through AI-Enabled Integration of Human Genetics & Multimodal Data Multimodal & AI-enabled precision medicineBiomarker discovery & translation Panel Wed Oct 7 9:00am Applying AI & Advanced Data Analytics to Transform Biomarker Discovery & Clinical Trial Strategy for Improved Precision Medicine Programs Multimodal & AI-enabled precision medicineBiomarker discovery & translation |
Bioptimus Paris, France | ◇Program Partner |
Builds AI foundation models of biology, including H-Optimus for histology images and the multimodal M-Optimus model, used in research and drug discovery. | Talk Wed Oct 7 2:10pm From Spatial Atlases to Predictive Insights: Scaling Precision Medicine with the M-Optimus World Model Digital pathology & spatial biomarkersMultimodal & AI-enabled precision medicine |
Imagene AI Tel Aviv, Israel | ◇Panel Partner |
Builds AI pathology models and real-world data tools that predict cancer biomarkers from tissue images, including the LungOI lung cancer test. | Panel Wed Oct 7 3:10pm Realizing the Promise, Gaps & Platform Innovation for Precision Medicine at Scale from Global Technology Leaders Multimodal & AI-enabled precision medicine |
Lunit Seoul, South Korea | ◇Program Partner |
South Korean medical AI company with software for cancer screening images and AI analysis of tumor tissue biomarkers. | Talk Thu Oct 8 11:00am Can AI Predict ADC Response? Multimodal & AI-enabled precision medicineBiomarker discovery & translation |
Instantly find 20 buyers in multimodal & ai-enabled precision medicine
Get a list of who you should contact, their contact info, and what to say.
Totally free and instant, no sign up necessary!
Browse World CDx 2026 by
Organization type
Topic
Everyone
Not affiliated with or endorsed by World CDx or its organizers. Submit a correction